Emerging Roles of Piezo1 Channels in Bone: Cells and Diseases
Mechanotransduction, the process by which cells convert mechanical stimuli into biochemical signals, is fundamental to bone homeostasis. Among the key molecular players in this process, Piezo1, a mechanosensitive ion channel, has emerged as a critical regulator of bone biology. Recent research highlights its indispensable roles in bone development, remodeling, repair, and disease pathogenesis. This article synthesizes current knowledge on Piezo1’s functions across skeletal cell types and its implications for bone-related disorders, drawing on experimental models, molecular mechanisms, and clinical correlations.
Piezo1 in Skeletal Lineage Cells
Mesenchymal Stem Cells (MSCs)
Piezo1 governs the fate of bone marrow-derived MSCs (BMSCs), balancing osteogenesis and adipogenesis. Under hydrostatic pressure, Piezo1 activation promotes osteoblast differentiation by upregulating bone morphogenetic protein 2 (BMP2), while suppressing adipogenesis. Conversely, Piezo1 inhibition disrupts this equilibrium, impairing osteoblast formation and exacerbating bone resorption. In neonatal mice, Piezo1 deficiency in BMSCs leads to spontaneous fractures and defective bone architecture. Beyond differentiation, Piezo1 regulates MSC migration. Studies using dental pulp-derived MSCs (DP-MSCs) demonstrate that Piezo1-mediated calcium (Ca²⁺) influx triggers ATP release, activating purinergic P2 receptors and downstream pathways, including proline-rich tyrosine kinase 2 (PYK2) and mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK/ERK). This mechanism enhances MSC recruitment to sites of mechanical stress, facilitating tissue repair.
Osteoblasts
Piezo1 is highly expressed in osteoblasts and is essential for their mechanoresponse. Conditional knockout of Piezo1 in osteoblasts disrupts Ca²⁺ signaling, impairing bone formation, structural integrity, and biomechanical strength. In tail-suspended mice—a model of mechanical unloading—Piezo1 ablation mitigates bone loss, suggesting that reduced mechanical loading suppresses Piezo1 activity, thereby hindering osteogenesis. Clinically, reduced Piezo1 expression in osteoblasts correlates with osteoporosis (OP), underscoring its role in osteoblast dysfunction. Mechanistically, Piezo1 regulates Yes-associated protein (YAP)-dependent expression of type II and IX collagens, which are vital for osteoblast differentiation and bone matrix organization. Additionally, fluid shear stress activates Piezo1 in osteoblasts, inducing osteogenic transcription factor Runx2 via the AKT/GSK-3/β-catenin pathway.
Osteocytes
As mechanosensors embedded in the bone matrix, osteocytes rely on Piezo1 to translate mechanical cues into anabolic signals. Piezo1-deficient osteocytes exhibit reduced cortical thickness, cancellous bone volume, and impaired adaptive responses to mechanical loading. Pharmacological activation of Piezo1 with Yoda1, a selective agonist, enhances bone mass by increasing intracellular Ca²⁺ and suppressing sclerostin—a potent inhibitor of bone formation. Mechanical stretching downregulates sclerostin in osteocytes through Piezo1-dependent Akt phosphorylation. Furthermore, Piezo1 mediates fluid shear stress-induced activation of the NOTCH3 pathway in osteocytic MLO-Y4 cells, elevating osteoprotegerin (OPG) and reducing receptor activator of nuclear factor kappa-B ligand (RANKL), thereby inhibiting osteoclastogenesis.
Chondrocytes
Piezo1 exerts dual roles in chondrocyte biology. While Piezo1 knockdown promotes chondrocyte proliferation, its activation by Yoda1 or mechanical stretch inhibits proliferation and induces apoptosis. Excessive mechanical loading elevates intracellular Ca²⁺ and reactive oxygen species (ROS), accelerating chondrocyte senescence and cartilage degeneration. The endogenous peptide urocortin 1 (Ucn1) counteracts these effects by inhibiting Piezo1 via cyclic AMP (cAMP)-dependent suppression of phospholipase A2 (PLA2). In mice, chondrocyte-specific Piezo1 deletion causes premature osteoporosis, abnormal osteoblast morphology, and defective secondary spongiosa formation, highlighting its role in endochondral ossification.
Osteoclasts
Piezo1 in osteoclasts modulates bone resorption. Conditional knockout mice exhibit accelerated bone loss due to impaired YAP nuclear localization and reduced type II/IX collagen production. In orthodontic tooth movement models, Piezo1 upregulation in osteoclasts correlates with increased tartrate-resistant acid phosphatase (TRAP)-positive cells and RANKL/OPG ratios, indicating enhanced osteoclast activity.
Piezo1 in Bone Diseases
Osteoporosis (OP)
Piezo1 is a genetic determinant of bone mineral density. Its expression is diminished in OP patients, and Piezo1-deficient mice recapitulate OP phenotypes. Piezoelectric micro-vibration stimulation (PMVS; 120 Hz) ameliorates OP in ovariectomized mice by upregulating Piezo1 in osteoblasts and suppressing Dickkopf-related protein 1 (Dkk1), a Wnt pathway inhibitor. In simulated microgravity, Piezo1 downregulation disrupts the β-catenin/activating transcription factor 4 (ATF4) axis, impairing BMSC proliferation and osteogenesis.
Osteoarthritis (OA)
Mechanical overloading in OA upregulates Piezo1 in chondrocytes, exacerbating apoptosis and cartilage degradation. The G protein-coupled estrogen receptor (GPER) protects against OA by suppressing Piezo1 via YAP-mediated actin cytoskeleton remodeling. Interleukin-1α (IL-1α), a proinflammatory cytokine in OA, amplifies Piezo1 expression, increasing baseline Ca²⁺ and sensitizing chondrocytes to mechanical injury.
Osteosarcoma (OS)
Piezo1 acts as a tumor suppressor in OS. Mechanical stretch induces Piezo1-dependent apoptosis and suppresses OS cell proliferation. In nude mice, Piezo1 knockdown accelerates tumor growth, implicating Piezo1 loss in OS progression.
Translational Implications and Challenges
Piezo1’s centrality in bone mechanobiology positions it as a therapeutic target. In aerospace medicine, countering microgravity-induced bone loss may involve Piezo1 activation. In bone tissue engineering, optimizing post-implantation mechanical cues could enhance Piezo1-mediated osteogenesis. However, challenges persist:
- Mechanism Complexity: Piezo1’s interplay with pathways like YAP, Wnt, and NOTCH remains incompletely mapped.
- Disease Context: Piezo1’s roles vary across pathologies—protective in OP but detrimental in OA—necessitating context-specific strategies.
- Pharmacological Tools: While Yoda1 and GsMTx4 (a Piezo1 inhibitor) are research staples, their clinical applicability requires refinement.
Conclusion
Piezo1 channels are master regulators of bone homeostasis, orchestrating responses to mechanical stimuli across skeletal cell types. Their dysfunction underpins osteoporosis, osteoarthritis, and osteosarcoma, offering novel therapeutic avenues. Future research must unravel Piezo1’s signaling networks, optimize mechano-based therapies, and address translational barriers. As the field advances, Piezo1 stands poised to revolutionize the management of bone diseases and mechanobiology-driven disorders.
doi.org/10.1097/CM9.0000000000003483
Was this helpful?
0 / 0